Diagnostic delay does not influence survival of pancreatic cancer patients
نویسندگان
چکیده
منابع مشابه
Body mass index does not affect the survival of pancreatic cancer patients
AIM To evaluate the association of body mass index (BMI) with the overall survival of pancreatic ductal adenocarcinoma (PDAC) patients. METHODS A retrospective analysis of PDAC patients diagnosed in the National Cancer Center of China between January 1999 and December 2014 was performed. These patients were categorized into four BMI groups (< 18.5, 18.5-22.9, 23-27.4 and ≥ 27.5 kg/m2). χ2 tes...
متن کاملInfluence of "diagnostic delay" upon cancer survival: an analysis of five tumour sites.
STUDY OBJECTIVE The aim was to assess the relationship between survival, tumour stage, and the interval from first symptom to diagnosis (SDI, or duration of symptoms). DESIGN This was a retrospective follow up study of a cohort of patients registered in the tumour registry of the Hospital del Mar (Barcelona). SETTING Hospital based tumour registry, with patients derived mainly from the City...
متن کاملDelay of Treatment Initiation Does Not Adversely Affect Survival Outcome in Breast Cancer
PURPOSE Previous studies examining the relationship between time to treatment and survival outcome in breast cancer have shown inconsistent results. The aim of this study was to analyze the overall impact of delay of treatment initiation on patient survival and to determine whether certain subgroups require more prompt initiation of treatment. MATERIALS AND METHODS This study is a retrospecti...
متن کاملPancreatic ductal adenocarcinoma: long-term survival does not equal cure.
BACKGROUND Pancreatic ductal adenocarcinoma represents 90% of pancreatic cancers and is an important cause of cancer death in the United States. Operative resection remains as the only treatment providing prolonged survival, but even after a curative resection, 5-year survival rates are low. Our aim was to identify the prognostic factors for long-term survival after resection of pancreatic duct...
متن کاملSLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival
Expression of the solute carrier (SLC) transporter SLC22A3 gene is associated with overall survival of pancreatic cancer patients. This study tested whether genetic variability in SLC22A3 associates with pancreatic cancer risk and prognosis. Twenty four single nucleotide polymorphisms (SNPs) tagging the SLC22A3 gene sequence and regulatory elements were selected for analysis. Of these, 22 were ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: United European Gastroenterology Journal
سال: 2020
ISSN: 2050-6406,2050-6414
DOI: 10.1177/2050640619879004